NJIPLA & NYIPLA Joint Program: The New World Order -- Current Developments in Challenging and Defending Patents in the PTAB
The New World Order –– Current Developments in
Challenging and Defending Patents in the PTAB
Wednesday, December 2, 2015
Hotel Woodbridge at Metropark, Iselin, NJ*
EARN 6.5 PROFESSIONAL CLE CREDITS
FOR BOTH NEWLY ADMITTED & EXPERIENCED ATTORNEY
- Hot Breakfast Buffet will be served -
Morning CLE Registration (excludes lunch)
Topic 1 Overview of USPTO PTAB proceedings from District Court and PTAB judges - stats, trends/direction, and proposed PTAB rule changes
Moderator: Dorothy Auth, Partner, Cadwalader, Wickersham & Taft
|10:40-10:55 AM||Refreshment Break
Topic 2 PTAB Hot Topics in the Hi-Tech Space. The presentation will include an analysis of recent trends, statistics, and lessons learned; consideration of the PTAB’s new rules; best practices for identifying and challenging the identification of real parties-in-interest; and a lively discussion about whether IPRs are really an effective defensive measure against patent enforcement by NPEs.
Moderator: Mark Abate, Partner, Goodwin Procter
|11:45 AM - 12:15 PM||
Afternoon CLE Registration Only (includes lunch)
Introduction: Dorothy Auth, NYIPLA President
Topic 3 The US Congress has been grappling with changes to the patent law provisions regarding IPRs and other post-grant proceedings (among other patent- / AIA-related proposed legislation). Learn about this process – and its current status – from key practitioners and professional advocates / strategic counsel who’ve interacted with Congress on those changes. Explore the players and advocates on both sides of the proposed legislation, and the positions they took and the ways they garnered support for their positions.
Moderator: Jeffrey Butler, Acting General Counsel and Advisor, Sentient Lifesciences
Topic 4 Hedge-Fund Sponsored IPR Challenges to Pharmaceutical Patents: Should They Be Treated Like Every Other Filing? Many have criticized hedge-fund sponsored IPR challenges to patents covering approved pharmaceutical products as a means for the hedge funds to reap profits in the short term while chilling biotech and pharma innovation in the long term. What’s the evidence for and against? Are PTAB decisions focused on the merits of the filings alone an adequate response to properly balance the interests at stake?
Moderator: Annemarie Hassett, Executive Director, NYU School of Law, Engelberg Center
Closing Remarks Jon Chiodo, NJIPLA President
- Cocktails & Hors d'oeuvre will be served -
*Conveniently located a very-short walking distance from the Metropark Station servicing NJ Transit and Amtrak. For those traveling from NYC by train: The direct-access train takes about 30 minutes from NY Penn Station.
Hotel Woodbridge at Metropark
120 Wood Avenue South
Iselin, NJ 08830